Literature DB >> 33846202

Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era.

Richard S Taylor1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33846202     DOI: 10.1503/cmaj.78240

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1. 

Authors:  Pascal M Lavoie; Frederic Reicherz; Alfonso Solimano; Joanne M Langley
Journal:  CMAJ       Date:  2021-08-16       Impact factor: 8.262

2.  A comparative analysis of the epidemiology of influenza and respiratory syncytial virus in Russia, 2013/14 to 2018/19.

Authors:  Saverio Caini; Kirill Stolyarov; Anna Sominina; Elizaveta Smorodintseva; Lisa Staadegaard; John Paget; Daria Danilenko
Journal:  J Glob Health       Date:  2022-02-05       Impact factor: 4.413

3.  Potential resurgence of respiratory syncytial virus in Canada.

Authors:  Pascal M Lavoie; Frederic Reicherz; Alfonso Solimano; Joanne M Langley
Journal:  CMAJ       Date:  2021-07-26       Impact factor: 8.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.